GoAI
Get started
Wenzhou Kangning Hospital Co., Ltd. logo

Wenzhou Kangning Hospital Co., Ltd.

2120.HK

HKSEHealthcareMedical - Care Facilities

Open in GoAI

Latest quote

HK$9.065

+HK$0.15 · +1.68%

Aug 24, 4:08 PM HKT

2120.HK company overview

Regular session · HKT · Market data may be delayed.

Company profile

Company website

Wenzhou Kangning Hospital Co., Ltd. oversees and manages a broad array of healthcare facilities throughout the People's Republic of China. A core part of its mission involves providing specialized psychiatric care. The company's diverse operations also encompass real estate rental and sales, software development and IT solutions, hospital administration, forensic analysis, general medical provisions, and the retail of pharmaceutical products. Established in 1996, the organization was initially known as Wenzhou City Kangning Psychiatric Rehabilitation Hospital before officially adopting its current name, Wenzhou Kangning Hospital Co., Ltd., in October 2014. Its principal offices are situated in Wenzhou, PRC.

Industry
Medical - Care Facilities
Sector
Healthcare
Headquarters
CN
CEO
Lianyue Wang
Listed since
Nov 20, 2015
Employees
5,586

Market position

Day range

Current HK$9.065

52-week range

Current HK$9.065

Open
HK$8.98
Previous close
HK$8.915
Volume
8.8K
1.5× average
Average volume
5.86K
Average daily volume
Market cap
638.17M HKD
Beta
0.18
Market reference 1
50-day average
HK$7.8182
+15.95% above average
200-day average
HK$9.0945
-0.32% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
1.51B CNY
EV / EBITDA
6.58×
Earnings yield
8.68%
Free cash flow yield
38.92%

Profitability & efficiency

Return on equity
4.58%
Return on assets
1.80%
Return on invested capital
1.73%

Financial health

Current ratio
1.31×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends29%18%7%-4%Gross margin, FY2021: 25.36%Gross margin, FY2022: 23.77%Gross margin, FY2023: 25.76%Gross margin, FY2024: 26.50%Gross margin, FY2025: 25.16%Operating margin, FY2021: 7.13%Operating margin, FY2022: 1.10%Operating margin, FY2023: 6.36%Operating margin, FY2024: 4.56%Operating margin, FY2025: 5.24%Net margin, FY2021: 3.39%Net margin, FY2022: -1.63%Net margin, FY2023: 5.38%Net margin, FY2024: 3.97%Net margin, FY2025: 3.36%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 25.36%. Gross margin FY2022 23.77%. Gross margin FY2023 25.76%. Gross margin FY2024 26.50%. Gross margin FY2025 25.16%. Operating margin FY2021 7.13%. Operating margin FY2022 1.10%. Operating margin FY2023 6.36%. Operating margin FY2024 4.56%. Operating margin FY2025 5.24%. Net margin FY2021 3.39%. Net margin FY2022 -1.63%. Net margin FY2023 5.38%. Net margin FY2024 3.97%. Net margin FY2025 3.36%.

Income trends

Revenue

1.62B CNY-2.09%

Operating income

84.83M CNY+12.58%

Net income

54.4M CNY-17.09%
Income trends across reported periods1.82B CNY1.15B CNY479.33M CNY−192.07M CNYRevenue, FY2021: 1.3B CNYRevenue, FY2022: 1.48B CNYRevenue, FY2023: 1.6B CNYRevenue, FY2024: 1.65B CNYRevenue, FY2025: 1.62B CNYOperating income, FY2021: 92.5M CNYOperating income, FY2022: 16.39M CNYOperating income, FY2023: 101.45M CNYOperating income, FY2024: 75.35M CNYOperating income, FY2025: 84.83M CNYNet income, FY2021: 44.04M CNYNet income, FY2022: −24.22M CNYNet income, FY2023: 85.95M CNYNet income, FY2024: 65.61M CNYNet income, FY2025: 54.4M CNYFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 1.3B CNY. Revenue FY2022 1.48B CNY. Revenue FY2023 1.6B CNY. Revenue FY2024 1.65B CNY. Revenue FY2025 1.62B CNY. Operating income FY2021 92.5M CNY. Operating income FY2022 16.39M CNY. Operating income FY2023 101.45M CNY. Operating income FY2024 75.35M CNY. Operating income FY2025 84.83M CNY. Net income FY2021 44.04M CNY. Net income FY2022 −24.22M CNY. Net income FY2023 85.95M CNY. Net income FY2024 65.61M CNY. Net income FY2025 54.4M CNY.
Metric (CNY)FY2025FY2024FY2023FY2022FY2021
Revenue1.62B CNY1.65B CNY1.6B CNY1.48B CNY1.3B CNY
Cost of goods sold1.21B CNY1.22B CNY1.19B CNY1.13B CNY968.43M CNY
Gross profit407.62M CNY438.4M CNY411.14M CNY352.93M CNY329M CNY
Research and development30.12M CNY36.52M CNY32.47M CNY33.03M CNY27.96M CNY
Selling, general, and administrative54.04M CNY59.7M CNY68.56M CNY74.3M CNY51.75M CNY
Operating expenses322.78M CNY363.05M CNY309.68M CNY328.49M CNY236.51M CNY
Interest income820.59K CNY−4.02M CNY−1.52M CNY2.76M CNY9.79M CNY
Interest expense45.85M CNY41.6M CNY39.94M CNY45.15M CNY47.38M CNY
Depreciation and amortization83.09M CNY22.19M CNY113.55M CNY114.21M CNY62.81M CNY
Operating income84.83M CNY75.35M CNY101.45M CNY16.39M CNY92.5M CNY
Net income54.4M CNY65.61M CNY85.95M CNY−24.22M CNY44.04M CNY

Company facts updated Aug 24, 2026.

Earnings

Latest fiscal-year EPS
0.76
FY2025 · -13.64% year over year
Latest fiscal-year revenue
1.62B CNY
FY2025 · -2.09% year over year

Annual EPS trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual EPS trend1.30.710.12-0.47FY21FY22FY23FY24FY25

Annual revenue trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual revenue trend1.69B1.55B1.4B1.26BFY21FY22FY23FY24FY25

2120.HK peers

WuXi AppTec Co., Ltd. logo

2359.HK

WuXi AppTec Co., Ltd.

HK$197.7

-3.94%

Jiangsu Hengrui Pharmaceuticals Co.,Ltd logo

1276.HK

Jiangsu Hengrui Pharmaceuticals Co.,Ltd

HK$46.46

-3.61%

BeOne Medicines AG logo

6160.HK

BeOne Medicines AG

HK$221.4

-2.89%

WuXi Biologics (Cayman) Inc. logo

2269.HK

WuXi Biologics (Cayman) Inc.

HK$48.60

-4.71%

Hansoh Pharmaceutical Group Company Limited logo

3692.HK

Hansoh Pharmaceutical Group Company Limited

HK$31.06

-6.11%

Innovent Biologics, Inc. logo

1801.HK

Innovent Biologics, Inc.

HK$99.50

-2.83%

Continue in GoAI

Research 2120.HK

research.disclaimer